Juli xnumx: On July 12, 2022, GenScript ProBio (Brian Ho-sung Min, CEO), a global CDMO, and ACT Therapeutics (Seogkyoung-Kong, CEO), developing a next-generation chimeric antigen receptor (CAR)-T cell therapy platform targeting solid cancer, announced that they had entered into a strategic partnership MOU concerning the development of a new CAR-T cell therapies. The MOU was in regard to the development of new CAR-T cell therapies. Through the use of this memorandum of understanding (MOU), GenScript ProBio and ACT Therapeutics have come to an agreement to further their collaboration in the field of cell therapy.
ACT Therapeutics og GenScript ProBio er i gang med at underskrive en kontrakt om udvikling og produktion af plasmid- og virusvektorer til den første pipeline af ACT Therapeutics' Advanced CAR-T Platform (ACT-platform), som også vil blive bestilt til at producere råmaterialer for ACT Therapeutics' efterfølgende pipelines. Kontrakten vil dække produktionen af plasmider og virusvektorer til den første pipeline af ACT Therapeutics' Advanced CAR-T Platform.
Som et resultat af denne aftale er GenScript ProBio blevet ophøjet til status som en global partner, der er i stand til at understøtte ACT-platforme for ACT-terapi.
ACT-platformen er en næste generations celle- og genterapiteknologi, der retter sig mod cancerantigener ved at indsætte gener designet til at målrette disse antigener i immunceller. Disse gener leveres til immunceller gennem brug af virusvektorer. GenScript ProBio besidder en højkvalitets virusvektorprocesudvikling og en one-stop-serviceplatform til GMP-produktion, som begge er nødvendige for udviklingen af celle- og genterapi.
ACT Therapeutics’ ACT platform is an advanced CAR-T technology that has a next-generation structure that goes beyond the second-generation CAR-T cell therapy and targets existing blodkræft. This is accomplished by overcoming the immune suppression microenvironment of solid cancer and activating the immune cells that are surrounding the cancer. Several studies have also used animals to test the ACT platform to see how well it works and if it is safe. These studies have also confirmed that the platform can be used to treat solid cancer while staying in the immunosuppressive environment of that cancer. Additionally, it complements the shortcomings of the existing second-generation CAR-T, which makes it a competitive technology for the treatment of solid cancer.
ACT Therapeutics is a Korean bio venture company that has received initial investment through DAYLI Partners, Korea’s leading bio and healthcare venture capital, since its establishment in 2020, and has been recognized for its technology such as receiving pre-series A investment in Samho Green Investment. DAYLI Partners is Korea’s leading bio and healthcare venture capital since its establishment in 2020. At the moment, investment consultations are being held with various securities firms and venture capital companies in order to entice Series A investment.
Brian H. Min, CEO of GenScript ProBio, said, “We are very happy to cooperate with ACT therapeutics in strategic partnership, and we are looking forward to support ACT Therapeutics’ ACT platform as a global partner through our accumulated technology.”
Seogkyoung-Kong, administrerende direktør for ACT Therapeutics, sagde: "Vi har afsluttet forberedelserne til, at ACT-platformen kan opstå globalt gennem et strategisk partnerskab med GenScript ProBio. Vi vil fremskynde udviklingen af behandlinger rettet mod ildfaste og vanskelige kræftformer."
Om GenScript ProBio
GenScript ProBio is a subsidiary of GenScript Biotech Corporation, proactively providing end-to-end CDMO service from drug discovery to commercialization with proactive strategies, professional solutions and efficient processes in cell and gene therapy (CGT), vaccine discovery, biologics discovery and antibody protein drug development to accelerate drug development for customers. GenScript ProBio has established companies in the United States, the Netherlands, South Korea, Shanghai, Hong Kong, Nanjing and other places to serve global customers, and supported customers in the United States, Europe, Asia Pacific and other regions to obtain more than 30 IND approvals.
Mod missionen "Innovation gennem samarbejde" er GenScript ProBio forpligtet til at hjælpe kunder med at forkorte tidslinjen for udvikling af biologiske lægemidler fra opdagelse til kommercialisering, hvilket væsentligt sænker F&U-omkostninger og opbygger en sundere fremtid.
